Skip to content

Appointment of Chief Financial Officer

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Rob Quinn as Chief Financial Officer and…

Aptamer Group signs two substantial new contracts

24/01/2023 Contracts worth over £500,000 with the potential for downstream milestone and royalty/ licensing payments Aptamer Group plc, the developer of novel Optimer® binders to enable innovation…

The stability of aptamers

One of the key benefits of using aptamers instead of antibodies is how you store and use your reagent. Over the past 60 years the stability of oligonucleotides has…

Appointment of Interim Chief Commercial Officer

09/01/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer,…